Virological response after 6 week triple-drug regimens for hepatitis C: A proof-of-concept phase 2A cohort study

The Lancet

Volumn 385, Issue 9973, 2015, Pages 1107-1113

  Kohli, Anita ^a,b   Osinusi, Anuoluwapo ^b,e   Sims, Zayani ^a   Nelson, Amy ^c   Meissner, Eric G ^c   Barrett, Lisa L ^c,e   Bon, Dimitra ^f   Marti, Miriam M ^c   Silk, Rachel ^b   Kotb, Colleen ^b   Gross, Chloe ^b   Jolley, Tim A ^c   Sidharthan, Sreetha ^a   Petersen, Tess ^a   Townsend, Kerry ^c   Egerson, D'Andrea ^b   Kapoor, Rama ^b   Spurlin, Emily ^c   Sneller, Michael ^c   Proschan, Michael ^c   Herrmann, Eva ^f   Kwan, Richard ^c   Teferi, Gebeyehu ^g   Talwani, Rohit ^d   Diaz, Gabbie ^b,h   Kleiner, David E ^h   Wood, Brad J ^h   Chavez, Jose ^g   Abbott, Stephen ^g   Symonds, William T ⁱ   Subramanian, G Mani ⁱ   Pang, Phillip S ⁱ   McHutchison, John ⁱ   Polis, Michael A ^c   Fauci, Anthony S ^c   Masur, Henry ^a   Kottilil, Shyam ^c   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d INSTITUTE OF HUMAN VIROLOGY   (United States)

^e DALHOUSIE UNIVERSITY   (Canada)

^f GOETHE UNIVERSITY   (Germany)

^g Unity Health   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ Gilead Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; GS 9669; HEMOGLOBIN; LEDIPASVIR PLUS SOFOSBUVIR; LOW DENSITY LIPOPROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; UNCLASSIFIED DRUG; VEDROPREVIR; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; FURAN DERIVATIVE; GS-9451; GS-9669; LEDIPASVIR; QUINOLINE DERIVATIVE; RIBAVIRIN; SOFOSBUVIR; THIOPHENE DERIVATIVE; URIDINE PHOSPHATE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLACK PERSON; COHORT ANALYSIS; COMMON COLD; CONCENTRATION (PARAMETERS); CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; FATIGUE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; INTENTION TO TREAT ANALYSIS; LIMIT OF QUANTITATION; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MUTANT; NAUSEA; NIGHT SWEAT; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RELAPSE; SHOULDER PAIN; TREATMENT DURATION; VERTIGO; VIRAL CLEARANCE; VOMITING; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; FURANS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; QUINOLINES; RIBAVIRIN; RNA, VIRAL; THIOPHENES; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; VIRAL LOAD;

EID: 84925607745     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61228-9     Document Type: Article

References (32)

1. K Mohd Hanafiah, J Groeger, AD Flaxman, ST Wiersma Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 2013 1333 1342
2. HJ Alter, LB Seeff Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome Semin Liver Dis 20 2000 17 35
3. KV Kowdley, E Lawitz, I Crespo et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial Lancet 381 2013 2100 2107
4. KE Sherman, SL Flamm, NH Afdhal et al. Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
5. PY Kwo, EJ Lawitz, J McCone et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
6. M Sulkowski, DF Gardiner, M Rodriguez-Torres et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
7. E Lawitz, FF Poordad, PS Pang et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial Lancet 383 2014 515 523
8. EJ Gane, CA Stedman, RH Hyland et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection Gastroenterology 146 2014 736 743 e1.
9. E Lawitz, L Hazan, D Gruener et al. 1189 GS-9669, a novel NS5B non-nucleoside thumb site II inhibitor, demonstrates potent antiviral activity, favorable safety profile and potential for once-daily dosing J Hepatol 52 suppl 2 2012 S471
10. EJ Lawitz, JM Hill, T Marbury et al. A phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients Antivir Ther 18 2013 311 319
11. RG Knodell, KG Ishak, WC Black et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1 1981 431 435
12. J Guedj, AU Neumann Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics J Theor Biol 267 2010 330 340
13. J Guedj, H Dahari, L Rong et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Proc Natl Acad Sci USA 110 2013 3991 3996
14. WJ Conover Practical nonparametric statistics 3rd edn. 1999 Wiley Hoboken
15. E Lawitz, A Mangia, D Wyles et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
16. MW Fried, M Buti, GJ Dore et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study Hepatology 58 2013 1918 1929
17. EJ Gane, CA Stedman, RH Hyland et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N Engl J Med 368 2013 34 44
18. A Osinusi, EG Meissner, YJ Lee et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial JAMA 310 2013 804 811
19. E Lawitz, F Poordad, KV Kowdley et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1 J Hepatol 59 2013 18 23
20. GT Everson, KD Sims, M Rodriguez-Torres et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection Gastroenterology 146 2014 420 429
21. KV Kowdley, SC Gordon, KR Reddy et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 2014 1879 1888
22. KV Kowdley, E Lawitz, F Poordad et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1 N Engl J Med 370 2014 222 232
23. N Afdhal, KR Reddy, DR Nelson et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 2014 1483 1493
24. N Afdhal, S Zeuzem, P Kwo et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
25. K Chayama, S Takahashi, J Toyota et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 55 2012 742 748
26. AS Lok, DF Gardiner, E Lawitz et al. Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
27. F Poordad, E Lawitz, KV Kowdley et al. Exploratory study of oral combination antiviral therapy for hepatitis C N Engl J Med 368 2013 45 53
28. Y Suzuki, K Ikeda, F Suzuki et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options J Hepatol 58 2013 655 662
29. S Zeuzem, P Buggisch, K Agarwal et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C Hepatology 55 2012 749 758
30. S Zeuzem, V Soriano, T Asselah et al. Faldaprevir and deleobuvir for HCV genotype 1 infection N Engl J Med 369 2013 630 639
31. A Hill, S Khoo, J Fortunak, B Simmons, N Ford Minimum costs for producing hepatitis C direct acting antivirals, for use in large-scale treatment access programs in developing countries Clin Infect Dis 58 2014 928 936
32. Sunovion Latuda (lurasidone): package insert 2010 Sunovion Marlborough